Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFLA |
Texto Completo: | http://repositorio.ufla.br/jspui/handle/1/46357 |
Resumo: | Background: Gastric cancer is one of the most incident types of cancer worldwide and presents high mortality rates and poor prognosis. MYC oncogene overexpression is a key event in gastric carcinogenesis and it is known that its protein positively regulates CDC25B expression which, in turn, plays an essential role in the cell division cycle progression. Menadione is a synthetic form of vitamin K that acts as a specific inhibitor of the CDC25 family of phosphatases. Methods: To better understand the menadione mechanism of action in gastric cancer, we evaluated its molecular and cellular effects in cell lines and in Sapajus apella, nonhuman primates from the new world which had gastric carcinogenesis induced by N-Methyl-N-nitrosourea. We tested CDC25B expression by western blot and RT-qPCR. In-vitro assays include proliferation, migration, invasion and flow cytometry to analyze cell cycle arrest. In in-vivo experiments, in addition to the expression analyses, we followed the preneoplastic lesions and the tumor progression by ultrasonography, endoscopy, biopsies, histopathology and immunohistochemistry. Results: Our tests demonstrated menadione reducing CDC25B expression in vivo and in vitro. It was able to reduce migration, invasion and proliferation rates, and induce cell cycle arrest in gastric cancer cell lines. Moreover, our in-vivo experiments demonstrated menadione inhibiting tumor development and progression. Conclusions: We suggest this compound may be an important ally of chemotherapeutics in the treatment of gastric cancer. In addition, CDC25B has proven to be an effective target for investigation and development of new therapeutic strategies for this malignancy. |
id |
UFLA_2d181861461111e9cd89e5eca8a0b59d |
---|---|
oai_identifier_str |
oai:localhost:1/46357 |
network_acronym_str |
UFLA |
network_name_str |
Repositório Institucional da UFLA |
repository_id_str |
|
spelling |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancerPhosphatasesGastric cancerMenadioneMYC oncogeneSapajus apellaCâncer gástricoFosfatasesMacaco-pregoBackground: Gastric cancer is one of the most incident types of cancer worldwide and presents high mortality rates and poor prognosis. MYC oncogene overexpression is a key event in gastric carcinogenesis and it is known that its protein positively regulates CDC25B expression which, in turn, plays an essential role in the cell division cycle progression. Menadione is a synthetic form of vitamin K that acts as a specific inhibitor of the CDC25 family of phosphatases. Methods: To better understand the menadione mechanism of action in gastric cancer, we evaluated its molecular and cellular effects in cell lines and in Sapajus apella, nonhuman primates from the new world which had gastric carcinogenesis induced by N-Methyl-N-nitrosourea. We tested CDC25B expression by western blot and RT-qPCR. In-vitro assays include proliferation, migration, invasion and flow cytometry to analyze cell cycle arrest. In in-vivo experiments, in addition to the expression analyses, we followed the preneoplastic lesions and the tumor progression by ultrasonography, endoscopy, biopsies, histopathology and immunohistochemistry. Results: Our tests demonstrated menadione reducing CDC25B expression in vivo and in vitro. It was able to reduce migration, invasion and proliferation rates, and induce cell cycle arrest in gastric cancer cell lines. Moreover, our in-vivo experiments demonstrated menadione inhibiting tumor development and progression. Conclusions: We suggest this compound may be an important ally of chemotherapeutics in the treatment of gastric cancer. In addition, CDC25B has proven to be an effective target for investigation and development of new therapeutic strategies for this malignancy.SAGE Publishing2021-05-24T18:39:28Z2021-05-24T18:39:28Z2020-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfBONA, A. B. et al. Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer. Therapeutic Advances in Gastroenterology, [S. I.], v. 13, p. 1-13, 2020. DOI: https://doi.org/10.1177/1756284819895435.http://repositorio.ufla.br/jspui/handle/1/46357Therapeutic Advances in Gastroenterologyreponame:Repositório Institucional da UFLAinstname:Universidade Federal de Lavras (UFLA)instacron:UFLAhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessBona, Amanda BragaCalcagno, Danielle QueirozRibeiro, Helem FerreiraMuniz, José Augusto Pereira CarneiroPinto, Giovanny RebouçasRocha, Carlos Alberto MachadoLacreta Junior, Antonio Carlos CunhaAssumpção, Paulo Pimentel deRey Herranz, Juan AntonioRodriguez Burbano, Rommeleng2021-05-24T18:39:55Zoai:localhost:1/46357Repositório InstitucionalPUBhttp://repositorio.ufla.br/oai/requestnivaldo@ufla.br || repositorio.biblioteca@ufla.bropendoar:2021-05-24T18:39:55Repositório Institucional da UFLA - Universidade Federal de Lavras (UFLA)false |
dc.title.none.fl_str_mv |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer |
title |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer |
spellingShingle |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer Bona, Amanda Braga Phosphatases Gastric cancer Menadione MYC oncogene Sapajus apella Câncer gástrico Fosfatases Macaco-prego |
title_short |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer |
title_full |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer |
title_fullStr |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer |
title_full_unstemmed |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer |
title_sort |
Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer |
author |
Bona, Amanda Braga |
author_facet |
Bona, Amanda Braga Calcagno, Danielle Queiroz Ribeiro, Helem Ferreira Muniz, José Augusto Pereira Carneiro Pinto, Giovanny Rebouças Rocha, Carlos Alberto Machado Lacreta Junior, Antonio Carlos Cunha Assumpção, Paulo Pimentel de Rey Herranz, Juan Antonio Rodriguez Burbano, Rommel |
author_role |
author |
author2 |
Calcagno, Danielle Queiroz Ribeiro, Helem Ferreira Muniz, José Augusto Pereira Carneiro Pinto, Giovanny Rebouças Rocha, Carlos Alberto Machado Lacreta Junior, Antonio Carlos Cunha Assumpção, Paulo Pimentel de Rey Herranz, Juan Antonio Rodriguez Burbano, Rommel |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Bona, Amanda Braga Calcagno, Danielle Queiroz Ribeiro, Helem Ferreira Muniz, José Augusto Pereira Carneiro Pinto, Giovanny Rebouças Rocha, Carlos Alberto Machado Lacreta Junior, Antonio Carlos Cunha Assumpção, Paulo Pimentel de Rey Herranz, Juan Antonio Rodriguez Burbano, Rommel |
dc.subject.por.fl_str_mv |
Phosphatases Gastric cancer Menadione MYC oncogene Sapajus apella Câncer gástrico Fosfatases Macaco-prego |
topic |
Phosphatases Gastric cancer Menadione MYC oncogene Sapajus apella Câncer gástrico Fosfatases Macaco-prego |
description |
Background: Gastric cancer is one of the most incident types of cancer worldwide and presents high mortality rates and poor prognosis. MYC oncogene overexpression is a key event in gastric carcinogenesis and it is known that its protein positively regulates CDC25B expression which, in turn, plays an essential role in the cell division cycle progression. Menadione is a synthetic form of vitamin K that acts as a specific inhibitor of the CDC25 family of phosphatases. Methods: To better understand the menadione mechanism of action in gastric cancer, we evaluated its molecular and cellular effects in cell lines and in Sapajus apella, nonhuman primates from the new world which had gastric carcinogenesis induced by N-Methyl-N-nitrosourea. We tested CDC25B expression by western blot and RT-qPCR. In-vitro assays include proliferation, migration, invasion and flow cytometry to analyze cell cycle arrest. In in-vivo experiments, in addition to the expression analyses, we followed the preneoplastic lesions and the tumor progression by ultrasonography, endoscopy, biopsies, histopathology and immunohistochemistry. Results: Our tests demonstrated menadione reducing CDC25B expression in vivo and in vitro. It was able to reduce migration, invasion and proliferation rates, and induce cell cycle arrest in gastric cancer cell lines. Moreover, our in-vivo experiments demonstrated menadione inhibiting tumor development and progression. Conclusions: We suggest this compound may be an important ally of chemotherapeutics in the treatment of gastric cancer. In addition, CDC25B has proven to be an effective target for investigation and development of new therapeutic strategies for this malignancy. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-01 2021-05-24T18:39:28Z 2021-05-24T18:39:28Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
BONA, A. B. et al. Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer. Therapeutic Advances in Gastroenterology, [S. I.], v. 13, p. 1-13, 2020. DOI: https://doi.org/10.1177/1756284819895435. http://repositorio.ufla.br/jspui/handle/1/46357 |
identifier_str_mv |
BONA, A. B. et al. Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer. Therapeutic Advances in Gastroenterology, [S. I.], v. 13, p. 1-13, 2020. DOI: https://doi.org/10.1177/1756284819895435. |
url |
http://repositorio.ufla.br/jspui/handle/1/46357 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
SAGE Publishing |
publisher.none.fl_str_mv |
SAGE Publishing |
dc.source.none.fl_str_mv |
Therapeutic Advances in Gastroenterology reponame:Repositório Institucional da UFLA instname:Universidade Federal de Lavras (UFLA) instacron:UFLA |
instname_str |
Universidade Federal de Lavras (UFLA) |
instacron_str |
UFLA |
institution |
UFLA |
reponame_str |
Repositório Institucional da UFLA |
collection |
Repositório Institucional da UFLA |
repository.name.fl_str_mv |
Repositório Institucional da UFLA - Universidade Federal de Lavras (UFLA) |
repository.mail.fl_str_mv |
nivaldo@ufla.br || repositorio.biblioteca@ufla.br |
_version_ |
1807835211671535616 |